Answers are grounded in this paper and cite their sources.
In vitro study demonstrates enhanced GLP-1 signaling and gut barrier protection by Coleus forskohlii extract in Caco-2 cells, suggesting potential therapeutic utility for metabolic disorders.
Glucagon-like peptide-1 (GLP-1) is a key incretin hormone involved in glucose regulation and metabolic health. This study reports, for the first time, the GLP-1 enhancing potential of a standardized Coleus forskohlii extract (Leanskolin™, ≥ 10% forskolin) using differentiated Caco-2 cells. MTT assay was performed to assess the cytotoxicity of Leanskolin (25–500 µg/mL) in Caco-2 cells. Later, the cells were treated with non-cytotoxic concentrations (25, 50, and 100 µg/mL) for 24 h. Further, in vitro Dipeptidyl peptidase-4 (DPP-4) enzyme inhibition assay was performed. At 100 µg/mL, Leanskolin significantly upregulated Proglucagon (3.33-fold, p < 0.001) and GLP-1R (3.32-fold, p < 0.01) gene expression, indicating stimulation of endogenous GLP-1 signaling. The extract also markedly inhibited cellular DPP-4 activity and its gene expression ( p < 0.05 vs. control). In vitro DPP-4 inhibition assay revealed an IC₅₀ of 262.5 µg/mL of Leanskolin, suggesting potential to prolong GLP-1 bioavailability. Furthermore, Leanskolin modulated bitter taste receptor genes ( TAS2R38 , TAS2R43 , TAS2R14 ) in a concentration-dependent manner ( p < 0.05), implicating a role in nutrient sensing and enteroendocrine signaling. Leanskolin treatment (25–100 µg/mL, 24 h) did not alter TEER values but significantly reduced FITC-flux at 50 and 100 µg/mL ( p < 0.01), indicating improved barrier integrity. Importantly, the extract enhanced the expression of tight junction (TJ) proteins ( p < 0.05 vs. control). These findings highlight the multi-targeted potential of Leanskolin in promoting metabolic health via GLP-1 pathway activation, DPP-4 inhibition, and gut barrier support. This first report demonstrates integrated activity of this extract, offering promising insights into its therapeutic relevance for managing metabolic disorders.
No takes yet. Share an insight, caveat, or question.
Sudeep et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: